Anzeige
Mehr »
Samstag, 27.09.2025 - Börsentäglich über 12.000 News
Hot Stock: KI-Boom treibt Kupfer in neue Dimensionen - jetzt profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACMZ | ISIN: US4622221004 | Ticker-Symbol: ISI
Tradegate
26.09.25 | 19:17
54,58 Euro
-0,29 % -0,16
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
IONIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
IONIS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
54,2655,3626.09.
54,4854,9826.09.

Aktuelle News zur IONIS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrGoldman Sachs upgrades Ionis Pharmaceuticals stock to Neutral on pipeline potential2
MiIonis Pharmaceuticals stock price target raised to $68 by Leerink Partners5
DiIonis Pharma's Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study8
DiWhat Analysts Are Saying About Ionis Pharmaceuticals Stock4
DiGuggenheim hebt Kursziel für Ionis Pharmaceuticals nach positiven Studiendaten an6
DiH.C. Wainwright reiterates Buy rating on Ionis Pharmaceuticals stock3
MoIonis plots FDA filing after rare neurological disease candidate posts phase 3 win1
MoIonis stock surges after positive results from Alexander disease drug17
IONIS PHARMACEUTICALS Aktie jetzt für 0€ handeln
MoIonis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial2
MoIonis reports promising data from study of Alexander disease therapy1
MoIonis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease1
MoIonis and Sobi's Tryngolza gains approval in EU for FCS treatment5
MoIonis Pharmaceuticals stock gets EU approval for TRYNGOLZA, H.C. Wainwright maintains Buy2
MoIonis reports positive results for Alexander disease drug zilganersen3
MoIONIS PHARMACEUTICALS INC - 8-K, Current Report3
19.09.KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs2
19.09.Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome1
19.09.EU approves Ionis and Sobi's FCS treatment Tryngolza4
19.09.Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)263Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment...
► Artikel lesen
12.09.Ionis pharmaceuticals celebrates 10 years of adaptive event for rare diseases15
Weiter >>
124 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1